Scientific publications written by our academic customers summarizing studies successfully performed using our microneedle array products.

2022

47. Maria Mir, Andi Dian Permana, Ismaiel A. Tekko, Helen O. McCarthy, Naveed Ahmed, Asim. ur. Rehman, Ryan F. Donnelly,
"Microneedle liquid injection system assisted delivery of infection responsive nanoparticles: A promising approach for enhanced site-specific delivery of carvacrol against polymicrobial biofilms-infected wounds, " International Journal of Pharmaceutics, Volume 587, 2020, 119643.

Based on the results reported in this publication, some key benefits of the AdminPen microneedle array liquid injection devices are:
* Allowed delivery of larger volumes of nanoparticle suspension compared to solid microneedles. The hollow design enables connection to syringes for injection of formulations.
* Rapid and direct delivery of nanoparticles into skin layers. Ex vivo studies showed the devices delivered over 80% of the dose within 2 hours, compared to only 15% with topical hydrogel over 6 hours.
* Improved drug retention at the application site. In vivo studies showed up to 85% of nanoparticles remained in the skin 24 hrs after AdminPen injection, versus only 30% retained from a hydrogel.
* Delivered higher drug concentrations to skin. AdminPen 1500 gave 8.5 times higher skin concentrations compared to topical hydrogel in vivo.
* Different needle lengths (777, 1200, 1500 μm) provide control over injection depth. Longer needles like 1500 μm gave deeper delivery into dermis.
* Successfully inserted into skin and created microconduits for drug delivery, with 100% insertion efficiency seen.
* Rapid restoration of skin barrier after removal, with complete closure of pores within 10 minutes observed.
* Sterile, minimal skin trauma, avoids pain and infection risk compared to hypodermic needles.
In summary, the AdminPen devices seem beneficial for rapid, targeted, and painless delivery of larger volumes of drug nanoparticles into the skin at higher concentrations than topical formulations. The AdminPen 1500 μm device gave optimal delivery into deeper skin layers in this study.
Click here for Full Text (PDF)

46. Vo, Trinh Phuong, Gitika Panicker, Kimberly Braz-Gomes, Ashwin C. Parenky, Ira Rajbhandari, Mangalathu S. Rajeevan, Elizabeth R. Unger, Martin J. D’Souza, and Mohammad N. Uddin. 2022. "Enhanced Immunogenicity of Adjuvanted Microparticulate HPV16 Vaccines Administered via the Transdermal Route" Pharmaceuticals 15, no. 9: 1128.

The publication discusses the benefits of using AdminPatch microneedle array devices for vaccine delivery, particularly focusing on the HPV16 vaccine. Here are some key points and benefits based on the results presented in the publication:

Enhanced Immunogenicity:
* The AdminPatch microneedle array devices were used to deliver an HPV16 vaccine, which demonstrated enhanced immunogenicity in preclinical models.
* The microneedle delivery of the vaccine elicited robust immune responses, which were significantly higher than those observed with intramuscular injection.

Microparticulate Formulation:
* The study utilized a microparticulate formulation of the HPV16 E7 protein, which was delivered using the AdminPatch.
* This formulation, when combined with a saponin-based adjuvant, induced potent E7-specific CD8+ T cell responses and anti-E7 IgG antibody responses.

Tumor Protection and Regression:
* The microparticulate E7 vaccine, when administered with the AdminPatch, provided protection against E7-expressing tumor challenges and also mediated regression of established tumors.

Comparison with Traditional Methods:
* The AdminPatch microneedle delivery of the vaccine was compared with conventional intramuscular injection.
* The results indicated that the AdminPatch delivery method was superior in terms of eliciting immune responses and providing tumor protection.

Adjuvant Enhancement:
* The use of a saponin-based adjuvant was crucial in enhancing the immunogenicity of the microparticulate E7 vaccine.
* The adjuvant was particularly effective when administered via the AdminPatch, enhancing both humoral and cellular immune responses.

Safety and Tolerability:
* Although not explicitly mentioned in the summary, microneedle array devices like AdminPatch generally aim to offer a safer and more tolerable method of vaccine delivery, minimizing pain and discomfort associated with traditional needle injections.

Potential for Clinical Translation:
* The study suggests that the AdminPatch microneedle array, combined with the microparticulate E7 vaccine and adjuvant, has potential for clinical translation due to its efficacy in preclinical models.

Addressing Global Health Challenges:
* The technology and findings from this study could be pivotal in addressing global health challenges by providing an effective, safe, and potentially more accessible method of vaccine delivery.

These points highlight the potential of AdminPatch microneedle array devices in enhancing the immunogenicity of vaccines, providing robust immune responses, and offering an alternative to traditional vaccine delivery methods. The results suggest potential applications in developing effective vaccination strategies, particularly for HPV16, and possibly for other pathogens as well.
Click here for Full Text (PDF)

45. Heba Abd-El-Azim, Ismaiel A. Tekko, Ahlam Ali, Alyaa Ramadan, Noha Nafee, Nawal Khalafallah, Taifur Rahman, William Mcdaid, Rania G. Aly, Lalitkumar K. Vora, Steven J. Bell, Fiona Furlong, Helen O. McCarthy, Ryan F. Donnelly, "Hollow microneedle assisted intradermal delivery of hypericin lipid nanocapsules with light enabled photodynamic therapy against skin cancer," Journal of Controlled Release, Volume 348, 2022, Pages 849-869.

Here are the identified benefits of using AdminPen™ hollow microneedles liquid injection devices (600, 900, 1200, and 1500 μm):
* Efficient Intradermal Delivery: The AdminPen™ hollow microneedles (Ho-MNs) array and an in-house fabricated Ho-MN enabled efficient intradermal delivery of hypericin lipid nanocapsules (Hy-LNCs).
* Improved Physicochemical Properties: The Hy-LNCs were successfully formed with desirable properties such as a particle size of 47.76 ± 0.49 nm, PDI of 0.12 ± 0.02, and a high encapsulation efficiency of 99.67% ± 0.35.
* Enhanced Photoactivity: The Hy-LNCs demonstrated a 396-fold higher photoactivity compared to free hypericin.
* Increased Skin Drug Deposition: The use of AdminPen™ hollow microneedles liquid injection devices (Ho-MNs) resulted in a 7-fold higher skin drug deposition of Hy-LNCs.
* Greater Cellular Uptake: The Hy-LNCs showed significantly greater cellular uptake and higher photocytotoxicity compared to free hypericin.
* Remarkable Anti-tumor Effect: In vivo studies using a nude mouse model with transplanted tumors revealed that Hy-LNCs delivered by AdminPen™ hollow microneedles liquid injection devices (Ho-MN) exhibited a significant anti-tumor destruction (85.84%) after irradiation with 595 nm.
* Promising Approach for Skin Cancer Management: The combination of AdminPen™ hollow microneedles liquid injection devices (Ho-MNs) driven delivery of Hy-LNCs followed by irradiation presents a promising minimally invasive, effective, and site-specific approach for managing non-melanoma skin cancers.
In summary, the AdminPen™ hollow microneedles liquid injection devices (Ho-MNs) offer an efficient and effective method for intradermal delivery of hypericin lipid nanocapsules, enhancing their therapeutic potential in photodynamic therapy against skin cancer.
Click here for Full Text (PDF)

44. D’Sa, Sucheta, Kimberly Braz Gomes, Grace Lovia Allotey-Babington, Cemil Boyoglu, Sang-Moo Kang, and Martin J. D’Souza. 2022. "Transdermal Immunization with Microparticulate RSV-F Virus-like Particles Elicits Robust Immunity" Vaccines 10, no. 4: 584.

Here are the identified benefits of using the AdminPatch® 1200 microneedle array system for improving transdermal immunization with microparticulate RSV-F Virus-like Particles:
* Robust Immune Responses: The study demonstrated that the transdermal delivery of RSV-F VLP (with or without MPL®) using the AdminPatch® 1200 microneedle array system has the potential to trigger robust immune responses. The transdermal delivery of RSV-F VLP + MPL® was found to be more effective in clearing lung viral loads and preventing weight loss after an RSV challenge.
* Enhanced Vaccine Efficacy: At the cellular level, MPL® augmented the vaccine response in microparticulate form. This was evidenced by higher serum and lung antibody titers and lower lung viral titers in the vaccinated groups.
* Non-Invasive and Pain-Free Vaccination: The AdminPatch® 1200 microneedle array system offers a non-invasive and pain-free form of vaccination. Due to the short needle lengths, microneedles do not stimulate the nerve endings in the dermis, making the vaccination process more comfortable for the recipient.
* Improved Antigen Presentation and Recognition: The study hypothesized that the transdermal delivery of a novel vaccine via the incorporation of a viral antigen such as the RSV fusion (F) protein VLPs in a polymeric matrix might result in enhanced uptake by immune cells. This could also provide improved antigen presentation and recognition by the immune system.
* Advantages of Transdermal Delivery: The transdermal route has gained popularity due to its advantages related to patient compliance, ease of administration, lower doses, and the ability to benefit from the immunocompetence of the skin. In transdermal vaccination, dendritic cells and Langerhans cells residing in the dermis can engulf the antigen, leading to the activation of cellular immunity.
* Microneedle Patch Acceptability: The minimally-invasive delivery of vaccines via a microneedle patch, such as the AdminPatch® 1200, would be greatly acceptable for individuals, especially children with a phobia of needles.
In conclusion, the AdminPatch® 1200 microneedle array system offers a promising approach for the transdermal delivery of the RSV-F VLP microparticulate vaccine, potentially leading to robust immune responses and enhanced vaccine efficacy.
Click here for Full Text (PDF)

2021

43. Shivaprasad Gadag, Reema Narayan, Archana S. Nayak, Diana Catalina Ardila, Shilpa Sant, Yogendra Nayak, Sanjay Garg, Usha Y. Nayak,
"Development and preclinical evaluation of microneedle-assisted resveratrol loaded nanostructured lipid carriers for localized delivery to breast cancer therapy," International Journal of Pharmaceutics, Volume 606, 2021, 120877.

AdminPatch 600, 777, and 1200 microneedle arrays were successfully used for the delivery of resveratrol for breast cancer therapy. The demonstrated benefits of the AdminPatch 600, 777, and 1200 microneedle arrays (denoted as 600 MN, 777 MN, and 1200 MN in the manuscript) are the following:
* Localized Delivery: The microneedle array system facilitates the localized delivery of resveratrol (RVT) to breast tissues. This targeted approach ensures that the drug is delivered directly to the affected area, increasing its therapeutic efficacy.
* Improved Permeation: The study found that RVT delivered using the microneedle array AdminPatch 1200 showed a higher permeation of RVT across the skin compared to pure RVT. This suggests that the microneedle system enhances the skin's permeability to the drug.
* Reduced Skin Retention: The RVT-NLCs (nanostructured lipid carriers) delivered using the microneedle array AdminPatch 1200 resulted in lower skin retention compared to pure RVT. This means that more of the drug is able to penetrate deeper tissues rather than remaining on the skin's surface.
* Enhanced Anticancer Activity: The RVT-NLCs showed higher anticancer activity on MDA-MB-231 breast cancer cell lines compared to pure RVT. This indicates that the combination of the microneedle system and the nanostructured lipid carriers enhances the drug's ability to combat cancer cells.
* Inhibition of Cancer Cell Migration: The RVT-NLCs were found to inhibit the migration of MDA-MB-231 breast cancer cell lines. This suggests that the treatment not only kills cancer cells but also prevents them from spreading.
* Increased Drug Concentration: Preclinical studies demonstrated that RVT-NLCs delivered via microneedles resulted in a remarkable increase in the Cmax (maximum serum concentration), Tmax (time to reach maximum concentration), and AUC0-inf (area under the curve, indicating overall drug exposure). Additionally, there was a higher localization of the drug in breast tissue compared to pure RVT administered orally.
* Effective Strategy for Breast Cancer Therapy: The results suggest that administering RVT-NLCs using the AdminPatch microneedle array system is an effective strategy for localized delivery of RVT for breast cancer therapy.
The AdminPatch microneedle arrays, specifically the AdminPatch 600, AdminPatch 777, and AdminPatch 1200, offer several benefits in the delivery of resveratrol for breast cancer therapy. These benefits include improved drug permeation, reduced skin retention, enhanced anticancer activity, and increased drug concentration in the target area.
Click here for Full Text (PDF)

2019

42. Lipika Chablani, Suprita A. Tawde, Archana Akalkotkar, Martin J. D’Souza, "Evaluation of a Particulate Breast Cancer Vaccine Delivered via Skin," AAPS J (2019) 21: 12.

AdminPen microneedle array devices have demonstrated more effective delivery of a Particulate Breast Cancer Vaccine. The publication discusses the development and evaluation of a breast cancer vaccine delivered through the skin. Here are the key findings and benefits of using the AdminPen microneedle array device based on the summarized content:

Background and Motivation:
* Breast cancer is the second most common cancer in females globally.
* Current therapies have various limitations and adverse effects, leading to the exploration of immunotherapies.
* The study aims to evaluate a particulate breast cancer vaccine delivered via skin using a spray drying technique with murine breast cancer whole cell lysate as the antigen source.

Microneedle Delivery:
* The skin is a unique site for vaccination as it houses various immune cells for an efficient immune response.
* Microneedles are micron-sized needles that create aqueous conduits in the skin, allowing for the delivery of the vaccine to immune-competent skin layers.
* Microneedles are minimally invasive, causing limited local injection site discomfort.
* The AdminPatch® 1200 microneedle array was used to deliver the particulate vaccine in this study.

Results:
* The average size of the particulate vaccine was 1.5 µm, which resembled pathogenic species, aiding in phagocytosis and antigen presentation, leading to immune response activation.
* AdminPatch® 1200 microneedle array created aqueous conduits of 50 ± 10 µm to deliver the microparticulate vaccine to the skin layers.
* In vivo results showed a significantly higher concentration of serum IgG, IgG2a, and B and T cell (CD4+ and CD8+) populations in vaccinated animals compared to control animals (p < 0.001).
* Vaccinated animals demonstrated five times more tumor suppression than control animals, confirming the immune response activation and protection (p < 0.001).

Conclusion:
* The research suggests a potential pathway for individualized immunotherapy following surgical tumor removal to prolong relapse episodes.
Click here for Full Text (PDF)

2018

41. Tanja Ilić, Sanela Savić, Bojan Batinić, Bojan Marković, Markus Schmidberger, Dominique Lunter, Miroslav Savić, Snežana Savić, Combined use of biocompatible nanoemulsions and solid microneedles to improve transport of a model NSAID across the skin: In vitro and in vivo studies, European Journal of Pharmaceutical Sciences, Volume 125, 2018, Pages 110-119.
Click here for Full Text (PDF)

40. Olatunji, O., Olubowale, M. & Okereke C., Microneedle-assisted transdermal delivery of acetylsalicylic acid (aspirin) from biopolymer films extracted from fish scales, C. Polym. Bull. (2018) 75: 4103.
Click here for Full Text (PDF)

2017

39. C. Uppuluri, J. Devineni, T. Han, A. Nayak, K. J. Nair, B. R. Whiteside, D. B. Das, B. N. Nalluri, Microneedle-assisted transdermal delivery of Zolmitriptan: effect of microneedle geometry, in vitro permeation experiments, scaling analyses and numerical simulations, Drug Development and Industrial Pharmacy (2017), Volume 43, Number 8, pp. 1292-1303.
AdminMed's Note: There are several following issues in this publication:
* AdminPatch microneedle arrays have 1 cm2 active area in contrast to this publication incorrectly referencing 1.77 cm2 active area;
* AdminPatch 1200 has 43 (forty-three) microneedles located within 1 cm2 circular area while the publication incorrectly says that AdminPatch 1200 has 41 microneedles per 1.77 cm2;
* AdminPatch microneedle arrays have 3D hollow microneedle shape and not “Flat (2D)” as reported in this publication. AdminPatch microneedle and base thicknesses are incorrectly measured in this publication as well.
* The correct Reference 21 should be: Vadim V. Yuzhakov, Microneedle array, patch, and applicator for transdermal drug delivery, US Patent No. 7,658,728. Washington DC: U.S.Patent and Trademark Office; 2010.
Click here for Full Text (PDF)

38. B. N. Nalluri, C. Uppuluri, J. Devineni, A. Nayak, K. J. Nair, B. R. Whiteside, D. B. Das, Effect of microneedles on transdermal permeation enhancement of amlodipine, Drug Deliv. and Transl. Res. (2017) 7:383–394.
AdminMed's Note: There are several following issues in this publication:
* AdminPatch microneedle arrays have 1 cm2 active area in contrast to this publication incorrectly referencing 1.77 cm2 active area;
* AdminPatch 1200 has 43 (forty-three) microneedles located within 1 cm2 circular area while the publication incorrectly says that AdminPatch 1200 has 41 microneedles per 1.77 cm2;
* AdminPatch microneedle arrays have 3D hollow microneedle shape and not “Flat (2D)” as reported in this publication. AdminPatch microneedle and base thicknesses are incorrectly measured in this publication as well.
* The correct Reference 23 should be: Vadim V. Yuzhakov, Microneedle array, patch, and applicator for transdermal drug delivery, US Patent No. 7,658,728. Washington DC: U.S.Patent and Trademark Office; 2010.
Click here for Full Text (PDF)

37. P.-C. Hsu, C. Liu, A. Y. Song, Z. Zhang, Y. Peng, J. Xie, K. Liu, C.-L. Wu, P. B. Catrysse, L. Cai, S. Zhai, A. Majumdar, S. Fan, Y. Cui, A dual-mode textile for human body radiative heating and cooling. Sci. Adv. 3, e1700895 (2017).
Click here for Full Text (PDF)

36. M. Gkikas, R. K. Avery, C. E. Mills, R. Nagarajan, E. Wilusz, B. D. Olsen, Hydrogels That Actuate Selectively in Response to Organophosphates, Adv. Funct. Mater. 2017, 27, 1602784.
Click here for Full Text (PDF)

35. Uppuluri, C., Shaik, A., Han, T. et al., Effect of Microneedle Type on Transdermal Permeation of Rizatriptan, AAPS PharmSciTech (2017) 18: 1495.
Click here for Full Text (PDF)

2016

34. Brendan Koch, Ilaria Rubino, Fu-Shi Quan, Bongyoung Yoo, and Hyo-Jick Choi, Microfabrication for Drug Delivery, Materials. 2016; 9(8):646
Click here for Full Text (PDF)

33. Suprita A. Tawde, Lipika Chablani, Archana Akalkotkar, Martin J. D'Souza, Evaluation of microparticulate ovarian cancer vaccine via transdermal route of delivery, Journal of Controlled Release, Volume 235, August 2016, Pages 147-154

This study investigates the efficacy of a microparticulate ovarian cancer vaccine administered through transdermal and oral routes. The AdminPen™ 1200 microneedle liquid injection system, a metallic microneedle device comprised of an array of 43 metallic microneedles of 1100 nm length in a 1 cm sq area of a circular microneedle array made of SS316 stainless steel, was used for transdermal delivery. Here are the key benefits and findings related to the use of the AdminPen™ 1200 system in the study:

Enhanced Transdermal Delivery:
* The AdminPen™ 1200 system was used to deliver microparticulate vaccines transdermally, effectively bypassing the stratum corneum of the skin. This method facilitated the transport of macromolecules that cannot be delivered across the skin by passive diffusion alone.
* The microneedles created aqueous conduits in the skin, forming a passage for the vaccine antigens towards the immune-competent skin layers.

Painless Immunization:
* Due to their short needle length, the microneedles avoid contact with nerve endings in the dermis, offering a painless mode of immunization.

Improved Immunogenicity:
* The microparticulate delivery system used with the AdminPen™ enhanced the immunogenicity of the vaccine. Particulate antigens were shown to be more immunogenic than soluble antigens, resulting in higher cytotoxic T-lymphocytes (CTLs) responses against cancer cells.
* The microparticles were easily phagocytosed by antigen-presenting cells (APCs), mimicking the pathogen recognition process and triggering an immune response.

Effective Tumor Suppression:
* The study demonstrated significant tumor suppression with the transdermal vaccine. The inclusion of interleukins in the vaccine formulation further enhanced tumor suppression, particularly when the vaccine was administered via both transdermal and oral routes.

Humoral Immune Response:
* Immunization with the microparticulate vaccine generated a humoral immune response. Mice showed elevated IgG titers compared to controls, indicating an effective B-cell response. The addition of interleukins influenced the Th1/Th2 response, contributing to the vaccine's efficacy.

Potential for Combination Therapy:
* The study explored a combination of transdermal and oral vaccine administration, aiming to leverage the benefits of both immunization routes. This approach was found to be particularly effective when interleukins were included in the vaccine formulation.

Patient Compliance and Ease of Administration:
* Transdermal delivery using the AdminPen™ is non-invasive and patient-friendly, potentially improving patient compliance compared to traditional injection methods.

These findings underscore the potential of the AdminPen™ 1200 microneedle system in enhancing the delivery and efficacy of microparticulate vaccines, particularly in the context of cancer immunotherapy. The system's ability to facilitate painless, effective transdermal delivery could make it a valuable tool in various therapeutic applications.
Click here for Full Text (PDF)

32. Buchi Naidu Nalluri, Sirivalli Kosuri, Sai Sri Anusha Valluru, Chandra Teja Uppuluri, Ashraf Sultana Shaik, Microneedle Assisted Transdermal Delivery of Levodopa, Indian Journal of Pharmaceutical Education and Research., 2016; 50(2):287-294
Click here for Full Text (PDF)

31. Jennifer Zhang, Yan Wang, Jane Y. Jin, Simone Degan, Russell P. Hall, Ryan D. Boehm, Panupong Jaipan, Roger J. Narayan, Use of Drawing Lithography-Fabricated Polyglycolic Acid Microneedles for Transdermal Delivery of Itraconazole to a Human Basal Cell Carcinoma Model Regenerated on Mice, JOM, April 2016, Volume 68, Issue 4, pp 1128-1133

The publication titled "Use of Drawing Lithography-Fabricated Polyglycolic Acid Microneedles for Transdermal Delivery of Itraconazole to a Human Basal Cell Carcinoma Model Regenerated on Mice" by Jennifer Zhang et al. explores the use of microneedles for transdermal delivery of itraconazole to a human Basal Cell Carcinoma (BCC) model regenerated on mice. The study utilized two types of microneedles: polyglycolic acid microneedles and 316L stainless steel microneedles, which were purchased from AdminMed, Sunnyvale, CA, USA.

The AdminPen 900 316L stainless steel microneedle arrays used in the study contained 85 microneedles, each 800 microns tall, organized in a 1-cm² circular array. The study aimed to explore the effectiveness of using microneedles to facilitate the transdermal delivery of itraconazole, an antifungal agent that has also shown to inhibit the growth of BCC through suppression of the Sonic Hedgehog (SHH) signaling pathway.

Here are some key findings and benefits based on the summarized content of the publication:

Microneedle Facilitation for Transdermal Delivery:
* Microneedles were used to create channels in the skin, specifically the 15-µm-thick keratinized stratum corneum layer, which typically hinders the transport of pharmacologic agents through the skin.
* The use of microneedles minimizes tissue damage and bleeding due to their small dimensions and does not penetrate deeper skin layers, reducing pain.

Itraconazole Delivery:
* Itraconazole, which has antifungal properties and can inhibit the growth of BCC, was delivered to a human BCC model regenerated on mice using the microneedles.
* The study utilized a solution of itraconazole dissolved in 60% dimethylsulfoxane and 40% polyethylene glycol-400 for the treatment, which was facilitated by both polyglycolic acid microneedle arrays and stainless steel microneedle arrays.

Treatment Results:
* The epidermal tissues treated with both polyglycolic acid microneedles and stainless steel microneedles were markedly thinner than the control (untreated) graft tissue.
* The study indicates that microneedles may be used to facilitate transdermal delivery of itraconazole for localized treatment of BCC.

Microneedle Characteristics:
* The AdminPen 900 316L stainless steel microneedles were 800 µm tall and were organized in a 1-cm² circular array, containing 85 microneedles.
* The polyglycolic acid microneedles were fabricated using injection molding and drawing lithography, resulting in microneedles with sharp tips and heights of 641 µm ± 9.5 µm.

Potential Advantages:
* The use of microneedles for transdermal delivery of itraconazole may offer a localized treatment option for BCC, potentially minimizing systemic absorption and associated side effects.
* The microneedles, due to their small size and minimal penetration, are associated with low levels of pain and minimal tissue damage, offering a potentially patient-friendly method of drug delivery.

Click here for Full Text (PDF)

2015

30. Leeladurga, V, Teja, UC, Sultana, SKA, Sudeep, K, Anusha, VSS, Han, T, Nalluri, BN, Das, DB, Application of Microneedle Arrays for Enhancement of Transdermal Permeation of Insulin: In Vitro Experiments, Scaling Analyses and Numerical Simulations, AAPS PharmSciTech, 2015.
Click here for Full Text (PDF)

29. Naresh Modepalli, HN Shivakumar, KL Paranjothy Kanni, and S Narasimha Murthy, Transdermal iron replenishment therapy, Therapeutic Delivery, 2015, Vol. 6, No. 6, Pages 661-668.
Click here for Full Text (PDF)

28. Ololade Olatunji, Richard T. Olsson, Microneedles from Fishscale-Nanocellulose Blends Using Low Temperature Mechanical Press Method, Pharmaceutics, 2015, 7(4), 363-378;
Click here for Full Text (PDF)

27. Hiep X. Nguyen, Ajay K. Banga, Enhanced skin delivery of vismodegib by microneedle treatment, Drug Delivery and Translational Research, August 2015, Volume 5, Issue 4, pp 407-423.
Click here for Full Text (PDF)

26. Karmen Cheung, Geoff West, Diganta Bhusan Das, Delivery of large molecular protein using flat and short microneedles prepared using focused ion beam (FIB) as a skin ablation tool. Drug Delivery and Translational Research, August 2015, Volume 5, Issue 4, pp 462-467. DOI10.1007/s13346-015-0252-0
Click here for Full Text (PDF)

25. Nayak, A, Short, L, Das, DB (2015) Lidocaine permeation from a lidocaine NaCMC:gel microgel formulation in microneedle pierced skin: vertical (depth averaged) and horizontal permeation profiles, Drug Delivery and Translational Research, August 2015, Volume 5, Issue 4, pp 372-386.
DOI: 10.1007/s13346-015-0229-z
Click here for Full Text (PDF)

24. Ita, K. Transdermal Delivery of Drugs with Microneedles—Potential and Challenges. Pharmaceutics 2015, 7, 90-105. doi:10.3390/pharmaceutics7030090
Click here for Full Text (PDF)

23. Nayak, A., Das, D. B., Chao, T. C. and Starov, V. M. (2015), Spreading of a Lidocaine Formulation on Microneedle-Treated Skin. J. Pharm. Sci.. doi: 10.1002/jps.24625
Click here for Full Text (PDF)

22. Tao Han and Diganta Bhusan Das, "A New Paradigm for Numerical Simulation of Microneedle-Based Drug Delivery Aided by Histology of Microneedle-Pierced Skin," Journal of Pharmaceutical Sciences (2015)
Click here for Full Text (PDF)

21. Atul Nayak, Hiten Babla, Tao Han, and Diganta Bhusan Das, "Lidocaine carboxymethylcellulose with gelatine co-polymer hydrogel delivery by combined microneedle and ultrasound," Drug Delivery (2015)
Click here for Full Text (PDF)

20. Buchi N. Nalluri, Sai Sri Anusha, Sri R. Bramhini, J. Amulya, Ashraf S. Sultana, Chandra U. Teja and Digantha B. Das, "In Vitro Skin Permeation Enhancement of Sumatriptan by Microneedle Application" (2015), http://dx.doi.org/10.2174/1567201812666150304123150
http://www.eurekaselect.com/129118/article
Click here for Full Text (PDF)

2014

19. Hiep Nguyen, Ajay K. Banga, Conference Paper: "Enhanced Delivery of Vismodegib by Microneedle Treatment: Effect of Needle Length, Equilibration Time and Treatment Duration." 2014 AAPS Annual Meeting and Exposition, San Diego, California, November 2014
Click here for Full Text (PDF)

18. Hiep Nguyen, Ajay K. Banga, Conference Paper: "Effect of Microneedle Treatment on the In-vitro Skin Permeation of Vismodegib." The Third International Conference on Microneedles 2014, School of Pharmacy, University of Maryland, Baltimore, Maryland, USA, May 2014
Click here for Full Text (PDF)

17. Dongwei Zhang, Diganta B. Das, "Microneedle assisted microparticle delivery: experiments using a skin mimicking agarose gel." The Third International Conference on Microneedles 2014, School of Pharmacy, University of Maryland, Baltimore, Maryland, USA, May 2014, pp. 67-68.
Click here for Full Text (PDF)

16. Dongwei Zhang, Diganta B. Das, Chris D. Rielly. "Microneedle assisted micro-particle delivery by gene guns: Mathematical model formulation and experimental verification," Chemical Engineering Science (2014), ISSN 0009-2509, http://dx.doi.org/10.1016/j.ces.2014.06.031.
Click here for Full Text (PDF)

15. Dongwei Zhang, Chris D. Rielly, and Diganta B. Das. "Microneedle-assisted microparticle delivery by gene guns: experiments and modeling on the effects of particle characteristics," Drug Delivery (2014).
Click here for Full Text (PDF)

14. Cheung, K, Han, T, Das, DB. "Effect of Force of Microneedle Insertion on the Permeability of Insulin in Skin," Journal of Diabetes Science and Technology (2014).
Click here for Full Text (PDF)

13. Monika Kaur, Kevin B. Ita, Inna E. Popova, Sanjai J. Parikh, Daniel A. Bair, Microneedle-assisted delivery of verapamil hydrochloride and amlodipine besylate, European Journal of Pharmaceutics and Biopharmaceutics.
Click here for Full Text (PDF)

12. Zhang, Dongwei, Diganta B. Das, and Chris D. Rielly. "Microneedle Assisted Micro‐Particle Delivery from Gene Guns: Experiments Using Skin‐Mimicking Agarose Gel." Journal of pharmaceutical sciences (2014).
Click here for Full Text (PDF)

2013

11. Yuen, Clement, and Quan Liu. "Ag coated microneedle based surface enhanced Raman scattering probe for intradermal measurements." European Conferences on Biomedical Optics. International Society for Optics and Photonics, 2013.
Click here for Full Text (PDF)

10. Yuen, Clement, and Quan Liu. "Towards in vivo intradermal surface enhanced Raman scattering (SERS) measurements: silver coated microneedle based SERS probe." Journal of biophotonics (2013).
Click here for Full Text (PDF)

9. Zhang, Dongwei, Diganta B. Das, and Chris D. Rielly. "An Experimental Study of Microneedle‐Assisted Microparticle Delivery." Journal of pharmaceutical sciences 102.10 (2013): 3632-3644.
Click here for Full Text (PDF)

8. Tao Han, Diganta B. Das, "Permeability Enhancement for Transdermal Delivery of Large Molecule Using Low-Frequency Sonophoresis Combined with Microneedles." Journal of Pharmaceutical Sciences, Vol. 102, 3614–3622 (2013)
Click here for Full Text (PDF)

7. Juluri, Abhishek, et al. "Minimally invasive transdermal delivery of iron–dextran." Journal of pharmaceutical sciences 102.3 (2013): 987-993.
Click here for Full Text (PDF)

6. Ita, Kevin, Nanik Hatsakorzian, and Vladimir Tolstikov. "Microneedle-Mediated Delivery of Atenolol and Bisoprolol Hemifumarate." Journal of Nanopharmaceutics and Drug Delivery 1.1 (2013): 38-44.
Click here for Full Text (PDF)

5. Atul Nayak, Diganta B. Das, Goran T. Vladisavljević, "Microneedle-Assisted Permeation of Lidocaine Carboxymethylcellulose with Gelatine Co-polymer Hydrogel." Pharmaceutical Research, November 2013.
Click here for Full Text (PDF)

4. Singh, Neha D., and Ajay K. Banga. "Controlled delivery of ropinirole hydrochloride through skin using modulated iontophoresis and microneedles." Journal of drug targeting 21.4 (2013): 354-366.
Click here for Full Text (PDF)

2012

3. Modepalli, Naresh, et al. "Microporation and ‘Iron’tophoresis for Treating Iron Deficiency Anemia." Pharmaceutical research (2013): 1-10.
Click here for Full Text (PDF)

2011

2. Lipika Chablani, Suprita Tawde, Archana Akalkotkar and Martin J. D’Souza, Formulation of Novel Particulate Breast Cancer Vaccines using Spray Drying and In Vivo Evaluation of Vaccine Efficacy.
Click here for Full Text (PDF)

2010

A well-known journal Drug Delivery Technology published our paper describing AdminPen devices. Please click on the following link to read the publication reviewing AdminPen devices and the enabling AdminPatch microneedle technology:

1. Yuzhakov, Vadim V. "The AdminPen™ Microneedle Device for Painless & Convenient Drug Delivery." Drug Deliv. Technol 10.4 (2010): 32-36.
Click here for Full Text (PDF)